Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-05-10 Board/Management Inform…
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Mr. Robert Funsten (DIN: 08950420), Independent Director, retired yesterday i.e. May 9, 2021, on completion of his term as an Independent Director of the Company.
Board/Management Information Classification · 100% confidence The document is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about the retirement of an Independent Director, Mr. Robert Funsten, on completion of his term. It is an announcement related to changes in the company's board of directors. The document is short (1586 characters) and does not contain financial data or detailed reports. Therefore, it fits the category of Board/Management Information (MANG).
2021-05-10 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated May 10, 2021, announcing that Lupin Limited has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company for manufacturing and selling Lilly's drug Baricitinib in India. The document is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to material event disclosures. The content is a corporate announcement about a licensing agreement and does not contain financial statements, management discussion, or detailed financial data. It is not an annual or interim report, earnings release, or any other detailed financial filing. The document is a regulatory disclosure of a material event, fitting the category of Regulatory Filings (RNS). The document length is about 5164 characters, which is consistent with a detailed announcement but not a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-05-10 English
Lupin enters into Voluntary Licensing Agreement with Lilly to Expand Access for COVID-19 Treatment in India.
Regulatory Filings Classification · 95% confidence The document is a press release dated May 10, 2021, announcing that Lupin Limited has signed a royalty-free, limited, non-exclusive voluntary licensing agreement with Eli Lilly and Company for manufacturing and selling Lilly's drug Baricitinib in India. The document is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains no financial statements, no detailed financial analysis, no management discussion, or other report content. It is a regulatory disclosure of a corporate event (licensing agreement) rather than a financial report or earnings release. The document length is about 5,158 characters, which is relatively short and consistent with an announcement. Therefore, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-05-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication dated May 4, 2021, addressed to stock exchanges (BSE and NSE) informing about an upcoming Annual Investor Communication scheduled for May 13, 2021. It mentions that transcripts of the call will be filed later. The document does not contain any financial data or detailed report content but is an announcement of an event and future filing. The length is only 1502 characters, which is quite short and fits the pattern of an announcement rather than a full report or transcript. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about an upcoming investor call and transcript filing, not the transcript itself or a financial report.
2021-05-04 English
Annual Investor Communication FY 2021 - Thursday, May 13, 2021 at 17.30 hrs (IST).
Regulatory Filings Classification · 95% confidence The document is a short communication dated May 4, 2021, addressed to stock exchanges, informing about an upcoming Annual Investor Communication scheduled for May 13, 2021. It references a call and mentions that transcripts will be filed later. The document does not contain any financial data or detailed report content but serves as a notification of an event and future filing. Given the short length (1502 characters) and the nature of the content as an announcement rather than the report or transcript itself, it fits best as a Regulatory Filing (RNS) under SEBI regulations.
2021-05-04 English
Board Meeting — Financial Results/Dividend/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notice from Lupin Limited to stock exchanges about an upcoming Board of Directors meeting scheduled for May 12, 2021. The purpose of the meeting includes considering and taking on record the audited standalone and consolidated financial results for the quarter and year ended March 31, 2021, and recommending a dividend if any. The document is short (1432 characters) and serves as an announcement of a future event rather than containing any financial data or results itself. It does not contain the financial results or detailed report but only informs about the meeting where these will be discussed. According to the 'MENU VS MEAL' rule, this is an announcement related to a report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for such regulatory announcements that do not fit other specific categories.
2021-05-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.